Pascal Soriot budgets a final £100M to finish AstraZeneca's new HQ — now 9 years and £1B-plus in the making
What’s another £100 million when you’ve already gone three times over budget?
Just another rounding number for AstraZeneca, which is still running up the tab on its gleaming new R&D/HQ in Cambridge, UK.
The Times spotlighted the fresh outlay included in the pharma giant’s annual report, with a reminder of the initial budget and completion date — £330 million in 2016. But AstraZeneca is reaching deeper now to pay for lab equipment, furniture and other finish-outs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.